Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings From the QPGx-CARES Initiative

Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings From the QPGx-CARES Initiative

<h3 dir="ltr">Purpose</h3><p dir="ltr">CYP2C19 loss-of-function (LoF) alleles are associated with increased cardiovascular risk in clopidogrel-treated percutaneous coronary intervention (PCI) patients. Despite the guidelines recommendation for newer P2Y12 inhibi...

Full description

Saved in:
Bibliographic Details
Main Author: Rania Abdel-latif (18295396) (author)
Other Authors: Wadha Al Muftah (3466304) (author), Shaban Mohammed (14150130) (author), Toka AlHsson (22963138) (author), Daoud Al-Badriyeh (832403) (author), Radja Badji (14152548) (author), Awad Al-Qahtani (315456) (author), Abdul Rahman Arabi (12506942) (author), Said Ismail (1567891) (author), Moza Al Hail (2511859) (author), Jassim Al Suwaidi (284932) (author)
Published: 2025
Subjects:
Biomedical and clinical sciences
Cardiovascular medicine and haematology
Pharmacology and pharmaceutical sciences
Antiplatelet therapy
Cardiology
CYP2C19
Pharmacogenetics
Point-of-Care
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items